CMRX News 20.49 Chimerix Inc (CMRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chimerix Inc (CMRX) 20.49 $CMRX

Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of M. Michelle Berrey, M.D., M.P.H. to the position of President and Chief Executive Officer. Dr. Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests. In addition, Dr. Berrey will continue to serve as Chimerix's Chief Medical Officer.

Increased Earnings Estimates Seen for Chimerix (CMRX): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 8:20AM CDT
Stock of Chimerix looks promising, as it is seeing solid activity on the earnings estimate revision front

3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were  Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...

Chimerix Appoints Lisa Ricciardi to Board of Directors
GlobeNewswire - Tue Apr 01, 6:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Lisa Ricciardi to the Company's Board of Directors.

Chimerix to Present a Summary of Brincidofovir's (CMX001) Hematologic Safety at the Annual Meeting of the European Group for Blood and Marrow Transplantation
GlobeNewswire - Mon Mar 24, 3:15PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 - April 2, 2014 in Milan, Italy.

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection
GlobeNewswire - Fri Mar 14, 7:14PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.

Strength Seen in Chimerix (CMRX): Stock Soars 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:04AM CDT
Chimerix, Inc. was a big mover last session, as the company saw its shares rise over 18% on the day.

Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.

Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections
GlobeNewswire - Tue Mar 11, 6:57PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. FDA has committed to work expeditiously with Chimerix on the design of a pivotal Phase 3 study that would be a continuation of this pilot study. Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovir's potential in adenovirus infection. This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014.

Chimerix Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Fri Mar 07, 6:08AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year 2013.

Chimerix's Brincidofovir (CMX001) Safety and Antiviral Data Presented at 2014 BMT Tandem Meetings
GlobeNewswire - Fri Feb 28, 10:15AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the 2014 BMT Tandem Meetings related to its investigational antiviral with broad-spectrum activity, brincidofovir (CMX001). Brincidofovir's antiviral activity against adenovirus (AdV) and its pediatric safety and tolerability data from a randomized, controlled clinical study and Chimerix's expanded access program were presented on Thursday, February 27, 2104 during the Supportive Care Oral Abstracts Session. Brincidofovir is an investigational oral nucleotide analog in Phase 3 development, currently enrolling adult hematopoietic cell transplant (HCT) recipients in the SUPPRESS trial for the prevention of cytomegalovirus infection, with secondary endpoints including clinical and virologic evidence of DNA viral infections, including AdV, BK virus and other herpes viruses such as HHV-6 and varicella zoster virus that contribute to morbidity and mortality in the first year following HCT.

Chimerix (CMRX) Jumps: Stock Adds 6.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:51AM CST
Chimerix, Inc. was a big mover last session, as its shares rose just nearly 7% on the day.

Chimerix to Announce Fourth Quarter Financial Results on March 7, 2014
GlobeNewswire - Thu Feb 27, 6:45AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that it will report financial results for the fourth quarter ended December 31, 2013, on Friday, March 7, 2014, before the market opens. Chimerix's management team will host a live conference call and audio webcast at 8:30 a.m. ET on Friday, March 7, 2014 to discuss the Company's results in detail.

Chimerix to Present at the Cowen 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 3:33PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that Kenneth I. Moch, President and CEO of Chimerix, will present at the Cowen 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:40am EST at the Boston Marriott Copley Place in Boston.

Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings
GlobeNewswire - Fri Feb 21, 3:15PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum investigational antiviral, brincidofovir (CMX001), at the BMT Tandem Meetings being held February 26 - March 2, 2014 in Grapevine, Texas. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).

Chimerix to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 4:12PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that Kenneth I. Moch, President and CEO of Chimerix, will present at the 16 Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 4:30pm EST at the Waldorf Astoria in New York City.

CareFusion Initiated at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 1:50PM CST
Although CFN is well positioned to benefit from current trends in healthcare, we are concerned about continued pressure on margins and the effect of the transition of product line to Pyxis ES platform.

Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group
PR Newswire - Wed Dec 25, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 86

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 90

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 22

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 24

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 82

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 95

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from the Global MOOC Conference on Future Education Trends

Updated Category News Views 197

The 2025 Global MOOC and Online Education Conference Overview The 2025 Global MOOC and Online Education Conference took place at the National Autonomous University of Mexico (UNAM) and focused on the theme of breaking boundaries to reshape futures in education. This event gathered educators and leaders in the field to discuss the future of online learning, with a...

Continue Reading
Truist Securities Predicts Growth Surge for Amazon Stock

Updated Category News Views 105

Amazon.com Inc (NASDAQ: AMZN) caught the attention of traders when Truist Securities boosted its price target from $230 to $265 back in early 2024. This wasn’t just a haphazard bump; they backed it with analysis that showed Amazon’s North American revenue holding steady, proving that consumers still love their Prime subscriptions and shopping sprees. What's fueling...

Continue Reading
Exploring the Rise of Probiotics in Animal Nutrition Market

Updated Category News Views 217

Understanding the Growth of Probiotics in Animal Feed As the demand for sustainable and antibiotic-free farming practices increases, the global probiotics in animal feed market is experiencing remarkable growth. Recent projections indicate that this market is expected to rise significantly, reflecting a shift in agricultural practices aimed at enhancing animal health and...

Continue Reading
Ascidian Therapeutics Announces Key Appointment to Advance Eyecare

Updated Category News Views 324

Key Appointment and New Advisory Board at Ascidian Therapeutics Ascidian Therapeutics, a pioneering biotechnology company focused on rewriting RNA to combat human diseases, has made a significant announcement. They have appointed Dr. Murray A. Abramson as Chief Development Officer (CDO) and created an Ophthalmology Clinical Advisory Board. This strategic move aims to...

Continue Reading
Waymo's Latest Robotaxi Innovation Marks a New Self-Driving Era

Updated Category News Views 375

Waymo's New Robotaxi Launches with Advanced Self-Driving Features Alphabet Inc.'s autonomous ride-hailing company, Waymo, has taken a significant step by introducing its latest Robotaxi equipped with sixth-generation self-driving technology. This advanced vehicle is now undergoing rigorous testing to ensure its readiness for the ever-competitive self-driving market....

Continue Reading